Abciximab

Drug #776

Abciximab is a mouse or human chimeric monoclonal antibody that blocks IIb/IIIa receptors. It prevents clotting or sticking of platelets (blood cell) together. Abciximab is a new drug and has been approved by the FDA as an adjunctive therapy in patients undergoing high risk angioplasty and atherectomy.

← Previous drug Next drug →

Primary Characteristics

It is of Combo1 origin.

It belongs to Adenosine uptake inhibitor pharmacological group on the basis of mechanism of action.

Non-proprietary name: Abciximab.

Pharmacokinetics

Elimination: it is metabolised via by liver, plasma half-life is 10-30 minutes.

Indications

Abciximab is primarily indicated in conditions like A variety of solid tumors, Acute leukemia, Adjunct to angioplasty, Chronic lymphocytic leukaemia, Lymphomas, Moderate to severe reflux oesophagitis, Myocardial infarction prophylaxis, Secondry bacterial infection of acute bronchitis.

Abciximab is also indicated for secondary conditions like 5-fu therapy, Abdominal bleeding.

Contraindications

Abciximab is contraindicated in conditions like Thrombocytopenia, Cerebrovascular accident, Vasculitis, Bleeding diathesis, Intracranial neoplasm, Hypersensitivity, GI bleeding, Active internal bleeding, Severe uncontrolled hypertension.

Dosage

Abciximab's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.125 ug/kg/min	0.125 ug/kg/min	—	IV Inf	(Max. 10 micrograms/minute); for prevention of ischaemic complications start 10-60 minutes before percutaneous coronary intervention and continue infusion for 12 hours; for unstable angina start up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention
0.25 mcg/kg	0.25 mcg/kg	—	Slow IV	This is the initial dose to be given over one minute.
Paediatric Dosage (20kg)
0 – 0	—	—	—	Not Recommended in this Age Group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

5 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Abciximab in overdosage may give rise to further complications which include Sinus bradycardia , Thrombocytopenia .

Abciximab produces potentially life-threatening effects which include Bleeding , Anaphylaxis , Stroke. Careful monitoring is needed with proper medical management.

Abciximab is known to cause more or less tolerable side effects which are usually transient. These include Backache , Confusion, Fever, Hematoma, Hypotension , Nausea, Vasculitis, Vision disturbances, Vomiting .

Warnings / Precautions

Abciximab should be used with caution in patients with pre-existing illnesses, allergy, recent surgery or trauma. It should not be used if there is any bleeding (e.g. gastrointestinal bleeding) or history of stroke. Abciximab should be used carefully in patients weighing less than 75 Kg or older than 65 years or have a history of gastrointestinal disease. Use with caution during pregnancy and lactation.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

2 mg/ml

Storage Conditions

Abciximab should be stored Inj.

Drug Classification

1.10.2 — Anticoagulants/Platelet deaggregators

Manufacturers

Manufacturers of Abciximab in Pakistan:

Lilly Mission